{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:36Z","timestamp":1747181076502,"version":"3.40.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing cytokine storm.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and analysis:<\/jats:title>\n            <jats:p>We aim to conduct an open-label randomized controlled trial to evaluate the efficacy and safety of adding colchicine to tocilizumab among patients with severe COVID-19 pneumonia to reduce the rate of invasive mechanical ventilation and mortality. We will include patients with severe COVID-19 pneumonia who received tocilizumab according to our local guidelines. Enrolled patients will be then randomized in 1:1 to colchicine versus no colchicine. Patients will be followed up for 30 days. The primary outcome is the rate of invasive mechanical ventilation and will be determined using Cox proportional hazard model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>Given colchicine\u2019s ease of use, low cost, good safety profile, and having different anti-inflammatory mechanism of action than other IL-6 blockade, colchicine might serve as a potential anti-inflammatory agent among patients with severe COVID-19 pneumonia. This study will provide valuable insights on the use of colchicine in severe COVID-19 when added to IL-6 antagonists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>The Medical Research Center and Institutional Review Board at Hamad Medical Corporation in Qatar approved the study protocol (MRC-01-21-299). Results of the analysis will be submitted for publication in a peer-reviewed journal.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030843","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T14:01:37Z","timestamp":1664546497000},"page":"e30618","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0184","authenticated-orcid":false,"given":"Alaa","family":"Rahhal","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Najim","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Rochester Regional Health - Unity Hospital, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer Hussein","family":"Aljundi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Mahfouz","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumaya Mehdar","family":"Alyafei","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Awaisu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mhd, Baraa","family":"Habib","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Obeidat","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohanad Mohammed","family":"Faisal","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshaal Ali","family":"Alanzi","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Prabhakaran","family":"Nair","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areeg","family":"Elhassan","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Al-Dushain","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaaeldin Abdelmajid","family":"Abdelmajid","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Elfadil","family":"Abdelgader","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mahmoud Ahmed","family":"Moursi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Eid Nazzal","family":"Alharafsheh","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Ragheb Abou","family":"Kamar","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Goravey","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr Salah","family":"Omar","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery\/Cardiac Anaesthesia Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Abukhattab","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery\/Cardiac Anaesthesia Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Yahya","family":"Khatib","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Gaafar","family":"Mohamedali","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muna A. Rahman","family":"AlMaslamani","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Alemadi","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hamad Medical Corporation, Doha, Qatar."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5694\/mja2.50674","article-title":"COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS","volume":"213","author":"Gibson","year":"2020","journal-title":"Med J Aust"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"R5-20250504","article-title":"Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.","author":"Reyes","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"117905","DOI":"10.1016\/j.lfs.2020.117905","article-title":"Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: therapeutic implications","volume":"256","author":"Banu","year":"2020","journal-title":"Life Sci"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R11-20250504","first-page":"171","article-title":"Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update","volume":"131","author":"Prieto-Pe\u00f1a","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"106103","DOI":"10.1016\/j.ijantimicag.2020.106103","article-title":"Tocilizumab for severe COVID-19: a systematic review and meta-analysis","volume":"56","author":"Lan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine--Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Mart\u00ednez","year":"2018","journal-title":"Atherosclerosis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine, 2017","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatology"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.40.6.605","article-title":"Prolonged reduction in polymorphonuclear adhesion following oral colchicine","volume":"40","author":"Fordham","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"Deftereos","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/annrheumdis-2020-217712","article-title":"Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome","volume":"79","author":"Scarsi","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1093\/ofid\/ofab466.596","article-title":"Early predictors of intensive care unit admission among COVID-19 patients in Qatar","volume":"8","author":"Abuyousef","year":"2021","journal-title":"Open Forum Inf Dis"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMe2103108","article-title":"Interleukin-6 receptor inhibition in Covid-19- cooling the inflammatory soup","volume":"384","author":"Rubin","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:16:26Z","timestamp":1746335786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":24,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030843","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}